Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × balixafortide × Breast × Clear all

Phase

Status

Withdrawn 1 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 76 Cyclophosphamide 61 Capecitabine 61 Paclitaxel 57 Docetaxel 53 Fulvestrant 47 Letrozole 44 Carboplatin 39 pembrolizumab 35 Lapatinib 34 Doxorubicin 33 Vinorelbine 29 Bevacizumab 28 Anastrozole 26 exemestane 25 Tamoxifen 22 Albumin-Bound Paclitaxel 22 Gemcitabine 21 Radiotherapy 17 Taxes 16 pertuzumab 15 palbociclib 15 atezolizumab 15 130-nm albumin-bound paclitaxel 15 Magnetic Resonance Spectroscopy 14 Everolimus 14 Epirubicin 14 eribulin 12 Goserelin 12 Biopsy 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03786094 2023-11-01

FORTRESS

Spexis AG

Phase 3 Terminated

432 enrolled 13 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡